Effects of inhaled human insulin on airway lining fluid composition in adults with diabetes

Mark Chang Hwa Liu, R. J. Riese, K. Van Gundy, P. Norwood, B. E. Sullivan, P. F. Schwartz, J. G. Teeter

Research output: Contribution to journalArticle

Abstract

Inhaled human insulin (Exubera® (human insulin of rDNA origin) Inhalation Powder) causes small, early and reversible changes in pulmonary function in subjects with diabetes mellitus. The present study assessed whether changes occur in cellular and soluble constituents of airway lining fluid consistent with inflammation as a possible cause for Exubera®-associated lung function alterations. Two 31-week, open-label, sequential design phase 2 studies were conducted, one with 20 subjects with type 1 and one with 24 subjects with type 2 diabetes. After run-in, all subjects received subcutaneous insulin for 12 weeks, followed after 1 week by 12 weeks of Exubera®. Bronchoalveolar lavage fluid cell counts and protein constituents were determined at baseline, after 12 weeks of subcutaneous insulin and after 12 weeks of Exubera®. Baseline cellular and soluble constituents of lavage fluid were similar to those reported for nondiabetic adults. Exubera® produced no consistent clinically or statistically significant changes in total or differential lavage fluid cell counts or protein concentrations, even though Exubera®-associated changes in pulmonary function are known to be fully manifest within 12 weeks. Therefore, 12 weeks of Exubera® treatment is not associated with evidence of pulmonary inflammation. The treatment effects on lung function observed in Exubera® trials are not caused by lung inflammation. Copyright

Original languageEnglish (US)
Pages (from-to)180-188
Number of pages9
JournalEuropean Respiratory Journal
Volume32
Issue number1
DOIs
StatePublished - Jul 2008

Fingerprint

Insulin
Lung
Therapeutic Irrigation
Pneumonia
Cell Count
Exubera
Bronchoalveolar Lavage Fluid
Ribosomal DNA
Powders
Type 2 Diabetes Mellitus
Inhalation
Diabetes Mellitus
Proteins
Inflammation
Therapeutics

Keywords

  • Bronchoalveolar lavage
  • Bronchoscopy
  • Exubera®
  • Glycaemic control
  • Pulmonary function tests

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Medicine(all)

Cite this

Liu, M. C. H., Riese, R. J., Van Gundy, K., Norwood, P., Sullivan, B. E., Schwartz, P. F., & Teeter, J. G. (2008). Effects of inhaled human insulin on airway lining fluid composition in adults with diabetes. European Respiratory Journal, 32(1), 180-188. https://doi.org/10.1183/09031936.00129907

Effects of inhaled human insulin on airway lining fluid composition in adults with diabetes. / Liu, Mark Chang Hwa; Riese, R. J.; Van Gundy, K.; Norwood, P.; Sullivan, B. E.; Schwartz, P. F.; Teeter, J. G.

In: European Respiratory Journal, Vol. 32, No. 1, 07.2008, p. 180-188.

Research output: Contribution to journalArticle

Liu, MCH, Riese, RJ, Van Gundy, K, Norwood, P, Sullivan, BE, Schwartz, PF & Teeter, JG 2008, 'Effects of inhaled human insulin on airway lining fluid composition in adults with diabetes', European Respiratory Journal, vol. 32, no. 1, pp. 180-188. https://doi.org/10.1183/09031936.00129907
Liu, Mark Chang Hwa ; Riese, R. J. ; Van Gundy, K. ; Norwood, P. ; Sullivan, B. E. ; Schwartz, P. F. ; Teeter, J. G. / Effects of inhaled human insulin on airway lining fluid composition in adults with diabetes. In: European Respiratory Journal. 2008 ; Vol. 32, No. 1. pp. 180-188.
@article{2672c23ef20540008f29091929629fdc,
title = "Effects of inhaled human insulin on airway lining fluid composition in adults with diabetes",
abstract = "Inhaled human insulin (Exubera{\circledR} (human insulin of rDNA origin) Inhalation Powder) causes small, early and reversible changes in pulmonary function in subjects with diabetes mellitus. The present study assessed whether changes occur in cellular and soluble constituents of airway lining fluid consistent with inflammation as a possible cause for Exubera{\circledR}-associated lung function alterations. Two 31-week, open-label, sequential design phase 2 studies were conducted, one with 20 subjects with type 1 and one with 24 subjects with type 2 diabetes. After run-in, all subjects received subcutaneous insulin for 12 weeks, followed after 1 week by 12 weeks of Exubera{\circledR}. Bronchoalveolar lavage fluid cell counts and protein constituents were determined at baseline, after 12 weeks of subcutaneous insulin and after 12 weeks of Exubera{\circledR}. Baseline cellular and soluble constituents of lavage fluid were similar to those reported for nondiabetic adults. Exubera{\circledR} produced no consistent clinically or statistically significant changes in total or differential lavage fluid cell counts or protein concentrations, even though Exubera{\circledR}-associated changes in pulmonary function are known to be fully manifest within 12 weeks. Therefore, 12 weeks of Exubera{\circledR} treatment is not associated with evidence of pulmonary inflammation. The treatment effects on lung function observed in Exubera{\circledR} trials are not caused by lung inflammation. Copyright",
keywords = "Bronchoalveolar lavage, Bronchoscopy, Exubera{\circledR}, Glycaemic control, Pulmonary function tests",
author = "Liu, {Mark Chang Hwa} and Riese, {R. J.} and {Van Gundy}, K. and P. Norwood and Sullivan, {B. E.} and Schwartz, {P. F.} and Teeter, {J. G.}",
year = "2008",
month = "7",
doi = "10.1183/09031936.00129907",
language = "English (US)",
volume = "32",
pages = "180--188",
journal = "European Respiratory Journal, Supplement",
issn = "0903-1936",
publisher = "European Respiratory Society",
number = "1",

}

TY - JOUR

T1 - Effects of inhaled human insulin on airway lining fluid composition in adults with diabetes

AU - Liu, Mark Chang Hwa

AU - Riese, R. J.

AU - Van Gundy, K.

AU - Norwood, P.

AU - Sullivan, B. E.

AU - Schwartz, P. F.

AU - Teeter, J. G.

PY - 2008/7

Y1 - 2008/7

N2 - Inhaled human insulin (Exubera® (human insulin of rDNA origin) Inhalation Powder) causes small, early and reversible changes in pulmonary function in subjects with diabetes mellitus. The present study assessed whether changes occur in cellular and soluble constituents of airway lining fluid consistent with inflammation as a possible cause for Exubera®-associated lung function alterations. Two 31-week, open-label, sequential design phase 2 studies were conducted, one with 20 subjects with type 1 and one with 24 subjects with type 2 diabetes. After run-in, all subjects received subcutaneous insulin for 12 weeks, followed after 1 week by 12 weeks of Exubera®. Bronchoalveolar lavage fluid cell counts and protein constituents were determined at baseline, after 12 weeks of subcutaneous insulin and after 12 weeks of Exubera®. Baseline cellular and soluble constituents of lavage fluid were similar to those reported for nondiabetic adults. Exubera® produced no consistent clinically or statistically significant changes in total or differential lavage fluid cell counts or protein concentrations, even though Exubera®-associated changes in pulmonary function are known to be fully manifest within 12 weeks. Therefore, 12 weeks of Exubera® treatment is not associated with evidence of pulmonary inflammation. The treatment effects on lung function observed in Exubera® trials are not caused by lung inflammation. Copyright

AB - Inhaled human insulin (Exubera® (human insulin of rDNA origin) Inhalation Powder) causes small, early and reversible changes in pulmonary function in subjects with diabetes mellitus. The present study assessed whether changes occur in cellular and soluble constituents of airway lining fluid consistent with inflammation as a possible cause for Exubera®-associated lung function alterations. Two 31-week, open-label, sequential design phase 2 studies were conducted, one with 20 subjects with type 1 and one with 24 subjects with type 2 diabetes. After run-in, all subjects received subcutaneous insulin for 12 weeks, followed after 1 week by 12 weeks of Exubera®. Bronchoalveolar lavage fluid cell counts and protein constituents were determined at baseline, after 12 weeks of subcutaneous insulin and after 12 weeks of Exubera®. Baseline cellular and soluble constituents of lavage fluid were similar to those reported for nondiabetic adults. Exubera® produced no consistent clinically or statistically significant changes in total or differential lavage fluid cell counts or protein concentrations, even though Exubera®-associated changes in pulmonary function are known to be fully manifest within 12 weeks. Therefore, 12 weeks of Exubera® treatment is not associated with evidence of pulmonary inflammation. The treatment effects on lung function observed in Exubera® trials are not caused by lung inflammation. Copyright

KW - Bronchoalveolar lavage

KW - Bronchoscopy

KW - Exubera®

KW - Glycaemic control

KW - Pulmonary function tests

UR - http://www.scopus.com/inward/record.url?scp=52749089075&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=52749089075&partnerID=8YFLogxK

U2 - 10.1183/09031936.00129907

DO - 10.1183/09031936.00129907

M3 - Article

VL - 32

SP - 180

EP - 188

JO - European Respiratory Journal, Supplement

JF - European Respiratory Journal, Supplement

SN - 0903-1936

IS - 1

ER -